Curated News
By: NewsRamp Editorial Staff
March 10, 2026
SS Innovations Reports 106% Revenue Growth, Expands Robotic Surgery Access Globally
TLDR
- SS Innovations' SSi Mantra installations surged 119% in 2025, offering investors growth potential as the company expands into new markets and pursues FDA approval.
- SS Innovations' SSi Mantra system uses modular robotic arms with 3D 4K imaging and over 40 specialized instruments to perform various surgical procedures across ten countries.
- SS Innovations makes robotic surgery more affordable and accessible globally, performing over 7,885 surgeries including pediatric and cardiac procedures to improve healthcare outcomes.
- SS Innovations performed the first telesurgery using their Tele Surgeon Console and developed new 5mm instruments for delicate pediatric and cardiac surgeries.
Impact - Why it Matters
This announcement matters because it signals a significant shift in the surgical robotics industry toward more affordable and accessible technology. Traditional robotic surgery systems have been prohibitively expensive for many hospitals worldwide, limiting patient access to minimally invasive procedures that typically result in faster recovery times, less pain, and better outcomes. SS Innovations' success in India—where they've gained substantial market share—demonstrates that cost-effective alternatives can disrupt established players. Their progress toward U.S. and EU regulatory approvals could introduce meaningful competition in Western markets, potentially driving down prices and expanding robotic surgery availability. The company's focus on telesurgery innovations also addresses healthcare access disparities, allowing specialized surgeons to operate remotely on patients in underserved areas. For investors, this represents a growth story in the expanding $15+ billion surgical robotics market; for healthcare providers, it offers more affordable technology options; and for patients globally, it means increased access to advanced surgical care that can improve outcomes and reduce hospital stays.
Summary
SS Innovations International, Inc. (Nasdaq: SSII), a developer of innovative surgical robotic technologies, announced impressive unaudited financial results for the fourth quarter and full year 2025, demonstrating strong growth across key metrics. The company reported a 79.1% revenue increase to $14.5 million in Q4 2025 compared to the same period in 2024, while full-year revenue surged 105.7% to $42.5 million. Most notably, installations of their flagship SSi Mantra surgical robotic system grew dramatically, with 40 installations in Q4 2025 (up 81.8% year-over-year) and 103 installations for the full year (up 119.1% from 2024). The system's cumulative installed base reached 168 units across ten countries, having performed 7,885 surgeries including 120 telesurgeries, 390 cardiac procedures, and 121 pediatric surgeries.
CEO Dr. Sudhir Srivastava highlighted several significant achievements, including gaining substantial market share in India's surgical robotics sector, expanding into new global markets, and progressing toward regulatory approvals in the United States and European Union. The company has pioneered robotic telesurgery with innovations like the Tele Surgeon Console and MantraM mobile robotic telesurgery unit. Following the quarter's end, SS Innovations completed a private placement generating approximately $18.6 million in gross proceeds to fuel further growth. The company anticipates FDA review of their 510(k) premarket notification for the SSi Mantra by mid-2026 and expects to obtain European Union CE marking certification this year, positioning them for continued expansion.
The SSi Mantra system represents a technological breakthrough in making robotic surgery more affordable and accessible globally. This modular, multi-arm system features 3 to 5 robotic arms, an ergonomic surgeon command center, 3D 4K visualization, and compatibility with over 40 different robotic endo-surgical instruments. Recent developments include the successful completion of the first telesurgery using the Tele Surgeon Console in November 2025 and the submission of their FDA 510(k) application in December 2025 covering multiple surgical indications. The company also announced development of five new 5-millimeter surgical instruments for pediatric, cardiac, and head and neck procedures. For more information, visit their website at ssinnovations.com or follow them on LinkedIn.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, SS Innovations Reports 106% Revenue Growth, Expands Robotic Surgery Access Globally
